Aethlon Medical Inc
$ 2.32
0.43%
15 Apr - close price
- Market Cap 3,624,600 USD
- Current Price $ 2.32
- High / Low $ 2.37 / 2.20
- Stock P/E N/A
- Book Value 6.90
- EPS -50.09
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.63 %
- ROE -2.09 %
- 52 Week High 35.20
- 52 Week Low 1.36
About
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life- and organ-threatening diseases in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$4.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-13 | 2025-11-12 | 2025-08-12 | 2025-06-27 | 2025-02-12 | 2024-11-12 | 2024-08-14 | 2024-06-26 | 2024-02-14 | 2023-11-14 | 2023-08-10 | 2023-06-28 |
| Reported EPS | -2.45 | -3.74 | -0.85 | -3.44 | -0.13 | -0.2 | -0.34 | -0.91 | -1.37 | -1.22 | -0.14 | -0.1 |
| Estimated EPS | -2.01 | -1.08 | -0.73 | -1.11 | -0.2033 | -0.19 | -0.31 | -1.25 | -1.23 | -1.4 | -0.13 | -0.13 |
| Surprise | -0.44 | -2.66 | -0.12 | -2.33 | 0.0733 | -0.01 | -0.03 | 0.34 | -0.14 | 0.18 | -0.01 | 0.03 |
| Surprise Percentage | -21.8905% | -246.2963% | -16.4384% | -209.9099% | 36.0551% | -5.2632% | -9.6774% | 27.2% | -11.3821% | 12.8571% | -7.6923% | 23.0769% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AEMD
2026-04-04 15:40:41
Aethlon Medical Inc. (AEMD) reported progress in its Australian oncology trial, the expansion of its extracellular vesicle research, and advancements in hemopurifier compatibility. While the company maintained a stable financial position with approximately $7 million in cash, it experienced increased operating expenses and a larger operating loss compared to the previous year. The transcript covers the Q3 2026 earnings call, detailing both positive developments and financial challenges.
2026-04-01 23:10:11
Aethlon Medical director Chetan Shah forfeited 178 shares of common stock to cover tax withholdings related to the conversion of 268 vested restricted stock units. This non-market transaction occurred at a market price of $2.19 per share. Following this routine tax settlement, Chetan Shah directly holds 1,463 shares of Aethlon Medical common stock.
2026-04-01 23:10:11
Edward G. Broenniman, a director at Aethlon Medical (NASDAQ: AEMD), has forfeited 89 shares of common stock to cover tax withholdings. This disposition was related to the conversion of 357 vested restricted stock units (RSUs), with the shares valued at $2.19 each. After this transaction, Broenniman directly holds 1,915 shares of Aethlon Medical.
2026-04-01 23:10:11
Aethlon Medical director Nicolas Gikakis forfeited 178 shares of common stock for tax withholding purposes. This forfeiture occurred upon the conversion of 268 vested restricted stock units into common stock, with a market price of $2.19 per share used for the transaction. Following this disposition, Gikakis directly holds 1,464 common shares in Aethlon Medical.
2026-03-24 14:39:15
Aethlon Medical (NASDAQ: AEMD) announced that its independent Data Safety Monitoring Board (DSMB) has completed a safety review of the second cohort in its AEMD-2022-06 trial and recommended advancing to the third and final cohort. The review found no device-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs), confirming a favorable safety profile for its Hemopurifier device. Enrollment is now open for Cohort 3, where participants will receive three Hemopurifier treatments over one week to further evaluate safety, feasibility, and dosing parameters in solid tumor patients.
2026-03-24 14:39:15
This article provides an industry overview of novel immunotherapeutics, highlighting advancements from several companies. It features Aethlon Medical, Inc. (Nasdaq:AEMD) and its Aethlon Hemopurifier clinical trial, TuHURA Biosciences, Inc. (NASDAQ:HURA) and its new CMO, AstraZeneca (NYSE: AZN) with its EU approval for Imfinzi, and Elicio Therapeutics, Inc. (Nasdaq: ELTX) discussing its ELI-002 7P progress. The market for novel immunotherapeutics is experiencing rapid growth, projected to exceed $300 billion by 2033–2035.
